Get the Stockscreener App
0.2328
7.46%
-0.0188
After Hours:
.22
-0.0128
-5.48%
Tc Biopharm Holdings Plc Adr Stock (TCBP) Latest News
Check Out TC BioPharm (Holdings) plc ADR (TCBP)’s Trade Data Rather Than the Analysts’ Views - SETE News
TC BioPharm (Holdings) plc ADR (TCBP) Stock: A Year of Highs and Lows in the Market - The InvestChronicle
TC Biopharm Faces Potential Nasdaq Delisting Due to Bid Price Non-Compliance - TipRanks
TC Biopharm Announces Special Stock Dividend and Temporary Trading Halt - TipRanks
TC BioPharm advances in acquisition strategy - Investing.com India
What Analysts Think About TC BioPharm (Holdings) plc ADR (NASDAQ: TCBP)’s Potential Raise - Stocks Register
TC BioPharm Approves Key Resolutions to Enhance Strategic Flexibility - TipRanks
No Stopping Argo Blockchain Plc ADR (NASDAQ: ARBK)’s Stock Plunged? - Stocks Register
NIO Inc ADR (NYSE: NIO) Stock Forecast: Could Pass $8 In A Year - Stocks Register
If You Don’t Buy Safe Pro Group Inc (NASDAQ: SPAI) Now, You’ll Regret It Later - Stocks Register
Would I Buy Opendoor Technologies Inc (NASDAQ: OPEN) Stock At Any Time In The Future? - Stocks Register
Tempest Therapeutics Inc (NASDAQ: TPST) Investors Should Be Worried About This. - Stocks Register
Where Do Analysts See Gamestop Corporation (NYSE: GME) Heading? - Stocks Register
TC BioPharm Advances Strategic Financial Initiative with New ADS Offering - TipRanks
TC BioPharm Announces Key Shareholder Meeting - TipRanks
TC Biopharm files $100M mixed securities shelf - TipRanks
TC Biopharm Faces Financial Strains Amid Rising Costs - TipRanks
TC Biopharm awarded funding of $250,000 from G-Rex Grant Program - TipRanks
TC BioPharm advances cancer therapy trials, raises $8M By Investing.com - Investing.com South Africa
TC BioPharm advances cancer therapy trials, raises $8M - Investing.com India
TC Biopharm refutes social media claim, remains compliant with Nasdaq rules - TipRanks
TC BioPharm denies Nasdaq delisting rumors - Investing.com
TC Biopharm enters research pact with Dr. Carlos Maluquer de Motes - TipRanks
United States shares mixed at close of trade; Dow Jones Industrial Average down 0.80% - Investing.com India
TC Biopharm (Holdings) PLC – ADR trading halted, volatility trading pause - TipRanks
U.S. stocks mixed at close of trade; Dow Jones Industrial Average down 0.80% - Investing.com
TCBP Stock Update: TC BioPharm (Holdings) plc ADR’s Banking’s Market Struggles and Potential Opportunities - The InvestChronicle
TC Biopharm announces artificial intelligene initiative with Carnegie Mellon - TipRanks
TCBP Announces Site Opening of Guys and St. Thomas Hospital - StockTitan
TC Biopharm announces first patient completes full dose regimen in ACHIEVE trial - TipRanks
TC BioPharm to start preclinical studies on monkeypox therapy - Investing.com India
TC Biopharm intends to launch preclinical study for treatment of Mpox - TipRanks
TC BioPharm to begin monkeypox treatment studies - Investing.com
TCBP’s Market Moves: -77.03% YTD Growth, -42.22% 6-Month loss, 68.52% in 30 Days - The InvestChronicle
TC BioPharm (Holdings) plc ADR (TCBP)’s stock rises to 7.28 per share - US Post News
TC Biopharm doses five new patients in the ACHIEVE Phase 2b trial in UK - TipRanks
TC Biopharm Unveils New Pre-Funded Warrant - TipRanks
Was there any good news for TC BioPharm (Holdings) plc ADR (TCBP) stock in the last session? - US Post News
Balance Sheet Insights: TC BioPharm (Holdings) plc ADR (TCBP)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - The Dwinnex
TC BioPharm secures European patent for cell therapy - Investing.com India
TC BioPharm Regains Nasdaq Compliance - TipRanks
TC BioPharm meets Nasdaq equity requirement - Investing.com
TC Biopharm Unveils Pre-Funded Share Warrants - TipRanks
TC BioPharm Regains Compliance with Nasdaq Listing Rule 5550(b) - StockTitan
TC BioPharm secures $2 million in direct offering - Investing.com
TC Biopharm Announces Warrant Adjustment - TipRanks
TC Biopharm At Risk of Nasdaq Delisting - TipRanks
Upcoming Stock Splits This Week (August 5 to August 9) – Stay Invested - Yahoo Finance
0.82%
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):